HPV-Related Carcinoma Clinical Trial
Official title:
A Phase Ib/II Trial Evaluating the Combination of TG4001 and Avelumab in Patients With HPV-16 Positive Recurrent or Metastatic Malignancies.
The study will consist of two parts : In the phase Ib: safety will be assessed in consecutive cohorts of 3 to 6 patients at increasing doses of TG4001 in combination with avelumab according to a 3+3 design. There will be no intra-patient dose escalation. In the phase II part 1, evaluation of efficacy and further evaluation of safety of the combination of TG4001 and avelumab will be performed in a single arm of patients with recurrent or metastatic HPV-16 positive advanced malignancies. In the phase II part 2, evaluation of efficacy of the combination of TG4001 and avelumab will be performed in a randomized, open-label controlled study comparing TG4001 in combination with avelumab to avelumab alone in patients with HPV-16 positive advanced malignancies. In both phases, tumor response will be evaluated on local assessment using RECIST 1.1. All patients will be followed up until disease progression, death, or unacceptable toxicity, or study withdrawal for any reason, whichever occurs first.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04001413 -
Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients
|
Phase 2 | |
Recruiting |
NCT04857528 -
Detecting HPV DNA in Anal and Cervical Cancers
|
||
Recruiting |
NCT05247853 -
HPV Vaccine Effectiveness Study in Rwandan Women Living With HIV
|
||
Completed |
NCT03033550 -
Integrating Primary & Secondary Interventions for Cervical Cancer Prevention in Primary Care Settings
|
N/A | |
Recruiting |
NCT05973487 -
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
|
Phase 1 | |
Terminated |
NCT05061940 -
This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
|
||
Recruiting |
NCT03475953 -
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05686226 -
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
|
Phase 2 | |
Recruiting |
NCT03795610 -
Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT05814549 -
A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC)
|
||
Recruiting |
NCT05307939 -
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
|
Phase 2 | |
Recruiting |
NCT05262010 -
A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
|
Phase 3 | |
Recruiting |
NCT06157151 -
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
|
Phase 2 | |
Completed |
NCT03749720 -
HPV in Blood Samples From Cervical Cancer Patients.
|
N/A | |
Not yet recruiting |
NCT05976828 -
IBRX-042 In Subjects With HPV-Associated Tumors
|
Phase 1 | |
Not yet recruiting |
NCT05639972 -
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06454175 -
A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years
|
Phase 1 | |
Not yet recruiting |
NCT06465914 -
A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males
|
Phase 3 | |
Active, not recruiting |
NCT03978689 -
A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma
|
Phase 1 | |
Recruiting |
NCT06305676 -
Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC)
|